HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin : Secondary Analyses of the CALMER study

This item is licensed under:Creative Commons Attribution 4.0 International

Files in This Item:
JDI 12 1417–1424.pdf640.75 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/82878

Title: Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin : Secondary Analyses of the CALMER study
Authors: Cho, Kyu Yong Browse this author
Nomoto, Hiroshi Browse this author →KAKEN DB
Nakamura, Akinobu Browse this author →KAKEN DB
Kawata, Shinichiro Browse this author
Sugawara, Hajime Browse this author
Takeuchi, Jun Browse this author
Nagai, So Browse this author →KAKEN DB
Omori, Kazuno Browse this author
Tsuchida, Kazuhisa Browse this author
Miya, Aika Browse this author
Shigesawa, Ikumi Browse this author
Tsuchida, Kenichi Browse this author
Yanagiya, Shingo Browse this author
Kameda, Hiraku Browse this author →KAKEN DB
Yokoyama, Hiroki Browse this author
Taneda, Shinji Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Nishimoto, Naoki Browse this author →KAKEN DB
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: SGLT2 inhibitor
DPP-4 inhibitor
Post-Prandial Blood Glucose
Time in Range
Issue Date: 10-Aug-2021
Publisher: John Wiley & Sons
Journal Title: Journal of Diabetes Investigation
Volume: 12
Issue: 8
Start Page: 1417
End Page: 1424
Publisher DOI: 10.1111/jdi.13498
Abstract: Aims/Introduction We recently reported the beneficial effect of the combination of SGLT2 inhibitor and DPP‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus (T2DM). Additional favorable effects of combination therapy were explored in this secondary analysis. Materials and Methods The CALMER study was a multicenter, open‐label, prospective, randomized, parallel‐group comparison trial for T2DM involving continuous glucose monitoring (CGM) under meal tolerance tests (MTTs). Patients were randomly assigned to switch from teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group). The CGM metrics, including time in target range (TIR), were investigated. Results All 99 participants (mean age: 62.3 years; mean HbA1c: 7.4%) completed the trial. TIR was increased in the COMB group (71.2% to 82.7%, p<0.001). The extent of the reduction in time above target range (TAR) was significantly larger in the COMB group compared with the SWITCH group (?14.8% vs. ?7.5%, p<0.01). Area under the curve values for glucose at 120 min after all MTTs were significantly decreased in the COMB group compared with the SWITCH group (p<0.05). Conclusions SGLT2 inhibitor combined with DPP‐4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy.
Rights: http://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/82878
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University